Beclin-1 表达在肝细胞癌中的预后和临床病理价值：一项荟萃分析。

Prognostic and clinicopathological value of Beclin-1 expression in hepatocellular carcinoma: a meta-analysis.

机构信息

Department of Pathology, School of Basic Medicine, Medical College, Qingdao University, No. 308 Ningxia Road, Qingdao, 266071, Shandong, People's Republic of China.

Central Laboratories, Qingdao Municipal Hospital, Qingdao, 266071, Shandong, People's Republic of China.

出版信息

World J Surg Oncol. 2018 Aug 14;16(1):170. doi: 10.1186/s12957-018-1465-8.

BACKGROUND

The abnormal expression of Beclin-1 has recently been investigated in a variety of tumors. However, previous studies have obtained contradicting results regarding the clinical and prognostic value of Beclin-1 in hepatocellular carcinoma (HCC). We performed a meta-analysis to clarify the prognostic value of Beclin-1 and its correlations with clinical pathological parameters in HCC.

METHODS

Relevant studies were systematically retrieved from PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Wan Fang and Chinese VIP databases. We used the Newcastle-Ottawa scale (NOS) to estimate the quality of the involved studies.

RESULTS

Ten eligible studies with 1086 HCC patients were included in this study. Our results showed that decreased Beclin-1 expression in HCC related to histological grade [poor-undifferentiated vs. well-moderate: odds ratio (OR) = 2.34, 95% confidence interval (CI) = 1.65-3.32, P < 0.00001]. The pooled hazard ratio (HR) (HR = 1.43, 95% CI = 1.17-1.75, P = 0.0004) indicated that decreased Beclin-1 expression correlated with poor overall survival (OS).

CONCLUSIONS

This meta-analysis indicated that decreased Beclin-1 expression might relate to poor differentiation and unfavorable outcome in HCC.

背景

Beclin-1 的异常表达最近在多种肿瘤中得到了研究。然而，之前的研究对于 Beclin-1 在肝细胞癌（HCC）中的临床和预后价值得出了相互矛盾的结果。我们进行了一项荟萃分析，以阐明 Beclin-1 的预后价值及其与 HCC 临床病理参数的相关性。

方法

从 PubMed、EMBASE、中国国家知识基础设施（CNKI）、万方和中国 VIP 数据库中系统地检索相关研究。我们使用纽卡斯尔-渥太华量表（NOS）来评估纳入研究的质量。

结果

本研究纳入了 10 项符合条件的研究，共涉及 1086 例 HCC 患者。我们的结果表明，HCC 中 Beclin-1 表达降低与组织学分级相关[低分化/未分化与中高分化：比值比（OR）=2.34，95%置信区间（CI）=1.65-3.32，P<0.00001]。合并的风险比（HR）（HR=1.43，95%CI=1.17-1.75，P=0.0004）表明，Beclin-1 表达降低与总体生存不良相关。